Pharmafile Logo

Brilinta

- PMLiVE

Trial combining British and Russian COVID-19 vaccines could begin in February

AstraZeneca announced the clinical trial programme in December

- PMLiVE

Live Webinar: COVID-19 Has Changed Live Events Forever!

We invite you to join Impetus Digital and the Medical Affairs Professional Society (MAPS) on February 19, 10 am EST, for a thought-provoking webinar around the future of virtual events.

Impetus Digital

- PMLiVE

New dosing option for AZ’s Imfinzi approved in the EU and UK

Additional option extends dosing from two weeks to four weeks

- PMLiVE

AstraZeneca’s focus on diagnosing and managing chronic kidney disease

People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care

- PMLiVE

AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine

CHMP could reach a decision on opinion by 29 January

- PMLiVE

AZ/Oxford University COVID-19 vaccine wins emergency approval in India

In June 2020, AZ signed a licensing deal with the Serum Institute for the vaccine

- PMLiVE

First person in the UK given AstraZeneca/Oxford University COVID-19 vaccine

The vaccine can be stored at standard refrigerator temperatures

- PMLiVE

COVID-19 vaccine developers respond to new strain

Pfizer, Moderna and AstraZeneca suggest their respective vaccines should remain effective

- PMLiVE

AstraZeneca to acquire Alexion for $39bn

Deal will bolster AZ's portfolio with rare disease assets

- PMLiVE

The Lancet confirms effectiveness of AZ/Oxford University’s COVID-19 vaccine

Final average efficacy analysis found to be 70.4%

- PMLiVE

AZ divests European rights for cholesterol med Crestor to Grünenthal

Grünenthal will pay up to $350m for the rights

- PMLiVE

AZ, Oxford University face more scrutiny over COVID-19 vaccine data

WHO’s immunisations director says ‘more than a press release’ is needed

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links